

MEDICARE FORM

Trelstar[®] (triptorelin pamoate) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

For New Jersey HMO D-SNP: FAX: 1-833-322-0034 PHONE: 1-844-362-0934 For other lines of business:

Please use other form

Note: Trelstar is non-preferred.
The preferred product is Eligard.

Firmagon is also a preferred product.

| | ☐ Start of treatmer | | / / last treatment / | 1 1 | • | ····agon to aloo | a protettoa producti |
|---|---|---|---|---|---|--------------------------------------|----------------------|
| | equested By: | | | | : | Fax: | |
| A. PATIENT INFO | · | | | 1 110116 | · | 1 ax | |
| First Name: | RIVIATION | | Last Name: | | | DOB: | |
| Address: | | | 1 | City: | | State: | ZIP: |
| | | Mark Dhana | | | | | ZIF. |
| Home Phone: | | Work Phone: | | Cell Phone: | T | Email: | |
| | = | kgs Patient | t Height: inches | orcms | Allergies: | | |
| B. INSURANCE IN | | | D " 11 " | | | | |
| | #: | | Does patient have other coverage? | | | | |
| | Group #: | | If yes, provide ID#: Carrier Name: Insured: | | | | |
| Insured: | The Maria marria | 1 15 11. | | " | □ N | р. д. | |
| | ☐ No If yes, provid | de ID #: | IVIE | edicaid: Yes | ☐ No If yes, prov | ide ID #: | |
| C. PRESCRIBER I | NFORMATION | | Last Name: | | (Check On | | |
| | | | | | (CITECK OII | theck One): M.D. D.O. N.P. P.A. | |
| Address: | T_ | | | City: | T | State: | ZIP: |
| Phone: | Fax: | | St Lic #: | NPI #: | DEA #: | 1 | UPIN: |
| Provider Email: | | | Office Contact Name: | | | Phone: | |
| Specialty (Check o | one): Oncologist | Endocrinol | ogist 🗌 Other: | | | | |
| Place of Administr Self-administered Outpatient Infusion Center Nan Home Infusion C Agency Nat Administration co Address: City: Phone: TIN: NPI: E. PRODUCT INFO Request is for: Tre F. DIAGNOSIS INFO | d | an's Office one: State: ZI Fax: PIN: moate) Dose: e indicate primary | IP: | Physician Specialty Name: Address: City: Phone: TIN: NPI: Frequer any other where | ncy: e applicable. Other I | Retail Pharn Other State: Fax: PIN: | ZIP: |
| | ests (clinical docume | | | a in its <u>entirety</u> io | r all precertification | requests. | |
| Gender dysphoi Yes No Preservation of Yes No Prostate cancer Note: Trelstar is no Yes No Has | ria Is the requested medi Is the requested medi Yes ☐ No Is the ☐ Yes ☐ No Will Please indicate the Toovarian function Is the patient premend. Ton-preferred. The prefix the patient had a trial | cation being presc e patient undergoi the patient receive anner Stage of pub opausal and under ferred product is and failure, intolei | cribed for pubertal suppring gender reassignmen at the requested medication or the patient has reacted. | t? ion concomitantly thed: Stage I iso a preferred property to Eligard? | with gender affirming] Stage II ☐ Stage II roduct. | I □ Stage IV □ | Stage V ☐ Unknown |
| | | | | | | | |



MEDICARE FORM

Trelstar[®] (triptorelin pamoate) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

For New Jersey HMO D-SNP: FAX: 1-833-322-0034 PHONE: 1-844-362-0934 For other lines of business:

Please use other form

Note: Trelstar is non-preferred. The preferred product is Eligard. Firmagon is also a preferred product.

| Patient First Name | Patient Last Name | Patient Phone | Patient DOB | | | | | |
|--|--|---|-----------------------|--|--|--|--|--|
| G. CLINICAL INFORMATION (contin | ued) – Required clinical information mus | t be completed in its <u>entirety</u> for all prece | rtification requests. | | | | | |
| For Continuation Requests (clinical documentation required for all requests): | | | | | | | | |
| ☐ Gender dysphoria | | | | | | | | |
| Yes No Is the requested medication being prescribed for pubertal suppression in an adolescent patient? Yes No Is the requested medication being prescribed for pubertal suppression in an adolescent patient? | | | | | | | | |
| ☐ Yes ☐ No Will the patient receive the requested medication concomitantly with gender affirming hormones? | | | | | | | | |
| Please indicate the Tanner Stage of puberty the patient has reached: Stage I Stage II Stage III Stage IV Stage V Unknown | | | | | | | | |
| ☐ Preservation of ovarian function | | | | | | | | |
| ☐ Yes ☐ No Is the patient premenopausal and still undergoing chemotherapy? | | | | | | | | |
| ☐ Prostate cancer | | | | | | | | |
| ☐ Yes ☐ No Has the patient had prior therapy with Trelstar within the last 365 days? | | | | | | | | |
| Yes No Has the patient experienced clinical benefit to therapy while receiving the requested drug (e.g., serum testosterone less than 50 ng/dl)? | | | | | | | | |
| ☐ Yes ☐ No Has the patient experienced an unacceptable toxicity while receiving the requested drug? | | | | | | | | |
| H. ACKNOWLEDGEMENT | | | | | | | | |
| Request Completed By (Signature | Required): | | Date: // | | | | | |
| any insurance company by providing | | a medical procedure or service with the als material information for the purpose will penalties | | | | | | |

The plan may request additional information or clarification, if needed, to evaluate request.